International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 64-69 , January 2005

Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer?

  • Keith L. Miller, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Timothy D. Shafman, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Mitchell S. Anscher, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Su-Min Zhou, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Robert W. Clough, B.S.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Jennifer L. Garst, M.D.

      Affiliations

    • Department of Hematology-Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Jeffrey Crawford, M.D.

      Affiliations

    • Department of Hematology-Oncology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Julian Rosenman, M.D.

      Affiliations

    • Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA
    • ,
  • Mark A. Socinski, M.D.

      Affiliations

    • Department of Hematology-Oncology, University of North Carolina, Chapel Hill, NC, USA
    • ,
  • William Blackstock, M.D.

      Affiliations

    • Department of Radiation Oncology, Wake Forest University, Winston-Salem, NC, USA
    • ,
  • Gregory S. Sibley, M.D.

      Affiliations

    • Department of Radiation Oncology, Sibley Hospital, Washington, DC, USA
    • ,
  • Lawrence B. Marks, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    • Corresponding Author InformationReprint requests to: Lawrence B. Marks, M.D., Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA. Tel: (919) 668-5640; Fax: (919) 684-3953

Received 18 September 2003 ,Revised 16 February 2004 ,Accepted 18 February 2004.

References 

  1. Jemal A, Taylor M, Samuels A, et al.  Cancer Statistics 2003. CA Cancer J Clin. 2003;53:5–26
  2. Dillman RO, Herndon J, Seagren S, et al.  Improved survival on stage III non-small cell lung cancer (Seven year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial). J Natl Cancer Inst. 1996;88:1210–1215
  3. Sause W, Kolesar P, Taylor S, et al.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer (Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group). Chest. 2000;117:358–364
  4. Perez CA, Stanley K, Grundy G, et al.  Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung (Report by the Radiation Therapy Oncology Group). Cancer. 1982;50:1091–1099
  5. Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys. 1993;25:579–587
  6. Hayman JA, Martel MK, Ten Haken RK, et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy (Update of a phase I trial). J Clin Oncol. 2001;19:127–136
  7. Saunders M, Dische S, Barrett A, et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer (Mature data from the randomised multicenter trial). Radiother Oncol. 1999;52:137–148
  8. Maguire PD, Marks LB, Sibley GS, et al.  73.6 Gy and beyond (Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer). J Clin Oncol. 2001;19:705–711
  9. Cox JD, Azarnia N, Byhardt RW, et al.  A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy (Possible survival benefit with >69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small-cell lung carcinoma—Report of Radiation Therapy Oncology Group 83-11). J Clin Oncol. 1990;8:1543–1555
  10. Rosenman JG, Halle JS, Socinski MA, et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer (Technical issues and results of a phase I/II trial). Int J Radiat Oncol Biol Phys. 2002;52:348–356
  11. Belderbos JSA, De Jagier K, Heemsbergen WD, et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003;66:119–126
  12. Rosenzweig KE, Mychalczak B, Fuks Z, et al.  Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J. 2000;6:82–87
  13. Speiser BL, Spratling L. Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. Int J Radiat Oncol Biol Phys. 1993;25:589–597
  14. Hayakawa K, Mitsuhashi N, Saito Y, et al.  Short communication (Adverse chronic effects of high-dose irradiation on proximal bronchus in patients treated for bronchogenic carcinoma). Br J Radiol. 1993;66:477–479
  15. King SC, Acker JC, Kussin PS, et al.  High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer (Unusual toxicity and promising early results). Int J Radiat Oncol Biol Phys. 1996;36:593–599
  16. Socinski MA, Marks LB, Garst J, et al.  Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy (A preliminary report of phase I dose escalation trial from the Carolina Conformal Therapy Consortium). Oncologist. 2001;6(Suppl. 1):20–24
  17. Anscher MS, Marks LB, Shafman TD, et al.  Risk of long-term complications after TGF-beta 1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:988–995
  18. Trotti A, Byhardt R, Stetz J, et al.  Common Toxicity Criteria, version 2.0 (An improved reference to grading the acute effects of cancer treatment—Impact on radiotherapy). Int J Radiat Oncol Biol Phys. 2000;47:3–47
  19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  20. Rostom AY, Morgan RL. Results of treating primary tumours of the trachea by irradiation. Thorax. 1978;33:387–393
  21. Dechambre S, Dorzee J, Fastrez, J et al. Bronchial stenosis and sclerosing mediastinitis: An uncommon complication of external thoracic radiotherapy. Eur Respir J 1998;11:1188–1190
  22. Miller KL, Harrell JH. Obstructing endobronchial bands complicating radiation therapy for lung carcinoma. Chest. 1992;101:1714–1715
  23. Miller KL, Zhou SM, Barrier RC, et al.  Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2003;56:611–615
  24. Komaki R, Lee JS, Kaplan B, et al.  Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer (Preliminary results). Semin Radiat Oncol. 2002;12(Suppl. 1):46–49
  25. Antonadou D, Coliarakis N, Synodinou M, et al.  Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2002;51:915–922
  26. Yie ES, Williams ST, Malicki DM, et al.  Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol. 1996;149:1963–1970

☆ Supported in part by NIH Grants CA33541, CA69579, and CA83721-01 and GlaxoSmithKline.

PII: S0360-3016(04)00598-X

doi: 10.1016/j.ijrobp.2004.02.066

International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 64-69 , January 2005

Article Tools

* Image Usage & Resolution